Thomas O'Shaughnessy, Chair of the Management Board
Mr. O'Shaughnessy holds an MSc in Comparative Social Policy from Oxford University and has extensive expertise in health strategy and execution. As a former partner at Deloitte Canada, he led the health industry practice in British Columbia and played a critical role nationally, contributing significantly to the digital care team and the growth of the firm's health industry practice. With over twenty-three years of experience in strategy and operations, Mr. O'Shaughnessy has honed his skills in healthcare and life sciences, focusing on strategy development and execution, digital technology integration, and stakeholder engagement. His leadership at Carnarvon Strategies as Managing Principal was marked by specialized strategy execution and value creation in the healthcare sector. In addition, his tenure as President of Healthtech enabled significant business growth and the launch of digital health services in Canada. His remarkable career is marked by his commitment to health system integration and organizational strategy implementation.
Nico Mah, Chief Financial Officer & Corporate Secretary
Mr. Mah is a Chartered Accountant and has nearly eight years of public accounting and audit experience, having served as an Associate and then Manager with PricewaterhouseCoopers LLP, the global accounting, auditing, tax, transaction and consulting firm, from September 2015 to January 2023. He holds a Bachelor of Commerce degree with a major in Accounting from the University of Calgary and is a CPA (Designated) in Alberta, Canada.
Graydon Bensler, Director
Mr. Bensler is a financial professional and analyst with more than seven years of experience in financial advisory and financial management for both private and public U.S./Canadian companies and is a Chartered Financial Analyst (CFA). He is currently the CEO of Elevai Labs, a publicly-traded company on the NASDAQ exchange.
Dr. Richard Heinzl, Director
Dr. Heinzl is a physician, humanist, entrepreneur and author with a current focus on genomics, artificial intelligence and healthcare worldwide. He lives in the Greater Toronto Area and is currently CEO of My Next Health Inc., a next-generation AI company for functional genomics. He is the founder of the Canadian section of Doctors Without Borders. He was Global Medical Director at WorldCare Inc., a Boston-based virtual medicine company affiliated with Harvard. He is a graduate of McMaster University's Michael G. DeGroote School of Medicine and completed post-graduate degrees in global health at Harvard University and the University of Oxford.
Zachary Thomas Stadnyk, Director
Mr. Stadnyk is a distinguished public company executive with over fifteen years of experience leading multi-billion-dollar initiatives in the healthcare, wellness, technology, cannabis and private equity sectors. Mr. Stadnyk has been the Chair and a director of Right Season Investments Corp., a TSXV-listed venture capital, investment and advisory firm, since June 2024. Mr. Stadnyk most recently led the Life Sciences and Innovation divisions at TMX Group.
Maximilian Justus, Director
Mr. Justus is an officer of a public company with experience in the fashion and apparel industry. Mr. Justus has served as Chief Executive Officer and Director of Grounded People Apparel since 2020, where he has focused on driving strategic initiatives, overseeing operations and growing market share.
Dr. Michael Weinfeld, Advisory Board Member
Dr. Michael Weinfeld is a professor in the Department of Oncology at the University of Alberta and a senior scientist at Alberta Health Services with over 40 years of experience in cancer research. His laboratory is located at the Cross Cancer Institute in Edmonton, Alberta. His main area of research is DNA damage and repair, with a particular interest in translating discoveries into improving clinical outcomes of cancer therapy. His most recent research has focused on the development of drugs designed to reduce the ability of cancer cells to repair their DNA, thereby making them more susceptible to radiation and chemotherapy agents that damage DNA.
Dr. Fadia Saad, Consultant
Dr. Saad, PhD, MBA, is currently Chief Business Development Officer at ASEP Medical Holdings Inc. She is a scientist with a background in finance and has a wealth of experience in the biotechnology industry. During her 5 years with Aspreva Pharmaceuticals, she held 0 years of experience in the last 25 years, she has held senior product development/business development positions in several biotech companies focused on autoimmune disorders, gastroenterology, neurology, infectious diseases and oncology.
Dr. Fredrick West, Consultant in Technology Transfer
Dr. West holds the Allard Research Chair in Oncology in the University of Alberta Faculty of Medicine and Dentistry – Department of Oncology. His research is in chemical synthesis, focusing on developing the best methods for making structural modifications to organic molecules. This includes inventing new reactions, but also applying his synthetic knowledge to design and make biologically active compounds. Dr. West was an important member of the team that developed the PNKP inhibitor technology, and his research focused on the impact of inhibiting repair enzymes on cancer cells to chemotherapy, which allowed the use of lower, less toxic doses.
Empfehlung
Krisen, Kriege und wirtschaftliche Unsicherheit sorgen derzeit weltweit für Nervosität an den Börsen. Doch genau in solchen Zeiten entstehen oft die besten Chancen. Für mutige und strategisch denkende Anleger kann das die Gelegenheit sein, günstig einzusteigen, bevor sich die Lage wieder beruhigt. Denn häufig gilt an der Börse: Große Gewinne entstehen oft dann, wenn andere noch zögern.
Dabei richtet sich der Blick zunehmend auf einen Sektor, der unabhängig von konjunkturellen Schwankungen durch einen strukturellen Wachstumstreiber geprägt wird: die Onkologie. Krebs zählt weltweit zu den führenden Ursachen für Morbidität und Mortalität. Nach einer aktuellen Analyse der „International Agency for Research on Cancer” (IARC), der Weltgesundheitsorganisation, könnte die Zahl neu diagnostizierter Krebserkrankungen bis 2050 um mehr als 75 Prozent steigen. Global Cancer Observatory+3Weltgesundheitsorganisation+3The Lancet+3
Kein Wunder also, dass staatliche und private Investitionen in Forschung und Entwicklung in den letzten Jahren zugenommen haben, was sich unmittelbar in Förderprogrammen und intensivierten Kooperationen zwischen akademischen Einrichtungen und der Industrie widerspiegelt. Ein Paradebeispiel dafür dürfte Onco Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ) sein. Im Zentrum des Unternehmens steht eine patentierte Nanopartikel-Plattform der zweiten Generation, flankiert von einem Portfolio aus fünf “Krebspatenten”. Der therapeutische Fokus liegt auf der Behandlung von Fernmetastasen bei sporadischem Darmkrebs, einem medizinischen Bereich mit hohem ungedecktem Therapiebedarf. Dass Branchenschwergewichte wie „AstraZeneca Canada” eine Kooperation eingegangen sind und „Roche” eine Studie mitfinanziert hat, verleiht dem Frühphasen-Unternehmen wissenschaftliche Glaubwürdigkeit und dürfte die Grundlage für künftige Lizenzvereinbarungen legen.
Das Marktumfeld spielt dem Unternehmen dabei in die Hände:
Der globale Onkologiemarkt in den USA soll bis 2032 auf rund 479 Milliarden USD anwachsen. Allein das adressierbare Segment für Darmkrebstherapeutika wird auf rund 18 Milliarden USD geschätzt. Zahlen allein schaffen indes noch keinen Unternehmenswert, entscheidend ist vielmehr, ob ein “Biotech” die klinische Entwicklung operativ glaubwürdig vorantreibt:
Bei Onco Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ) verdichten sich die Hinweise darauf, denn das Unternehmen treibt seine klinische Entwicklungsstrategie sichtbar voran: Mit der Gründung einer eigenen Tochtergesellschaft in Australien und einer Kooperation mit “RDI Partners” stellt das Unternehmen die Weichen für die geplante “Phase-I-Studie”. Australien gilt in der Branche als attraktiver Standort für frühe klinische Programme, nicht zuletzt wegen effizienter Genehmigungswege und potenzieller steuerlicher Anreize. Onco Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ) baut damit eine belastbare Infrastruktur auf, um die “First-in-Human”-Entwicklung operativ und finanziell kontrolliert voranzubringen. Für Investoren könnte dies ein weiterer Schritt sein, der das Unternehmen näher an die klinische Umsetzung und damit an einen entscheidenden Werttreiber führt.
Nach einer Phase der Konsolidierung verdichten sich bei der Aktie Hinweise auf einen möglichen Turnaround. Für risikobewusste Anleger könnte sich damit eine aussichtsreiche Trade-Opportunity eröffnen.
.jpeg)
